Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Cogent Biosciences and increased the price target to $54.00 from $53.00.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sam Slutsky has given his Buy rating due to a combination of factors related to Cogent Biosciences’ lead asset and advancing pipeline. He highlights the FDA’s Breakthrough Therapy Designation for bezuclastinib plus sunitinib in second-line GIST following imatinib, which is supported by positive Phase 3 PEAK trial data and an NDA submission anticipated to complete in April 2026 under the RTOR framework. He also notes the planned mid-2026 launch of a Phase 2 study in first-line GIST patients with exon 9 mutations, where the bezuclastinib–sunitinib combination appears to offer superior inhibition versus imatinib and the potential for more comprehensive KIT mutant coverage.
More broadly, Slutsky underscores the value of Cogent’s systemic mastocytosis franchise, with an NDA already filed in non-advanced SM (also with BTD) and a separate NDA for advanced SM expected in the first half of 2026, supported by data from the SUMMIT and APEX trials slated for presentation at major conferences. He points to additional upside from earlier-stage assets, including an upcoming pan-KRAS(ON) inhibitor, a selective JAK2 V617F inhibitor, and FGFR2/3 inhibitor CGT4859 with Phase 1/2 data expected, which collectively expand the company’s long-term growth potential. After modest model updates, he raises his price target to $54 per share (from $53), reinforcing his positive view on the stock’s risk‑reward profile and supporting the Buy recommendation.
Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Olema Pharmaceuticals, and Cogent Biosciences. According to TipRanks, Slutsky has an average return of 40.4% and a 51.02% success rate on recommended stocks.
In another report released on January 15, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $42.00 price target.